High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Sorbye, Halfdan ^a   Dragomir, Anca ^b,c   Sundström, Magnus ^c   Pfeiffer, Per ^d   Thunberg, Ulf ^c   Bergfors, Monica ^b   Aasebø, Kristine ^a   Eide, Geir Egil ^e   Ponten, Fredrik ^c   Qvortrup, Camilla ^d   Glimelius, Bengt ^c  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MUTATION RATE; ONCOGENE K RAS; PATIENT SELECTION; PHYSICAL PERFORMANCE; POPULATION RESEARCH; PROSPECTIVE STUDY; TISSUE MICROARRAY; WILD TYPE; COLORECTAL TUMOR; GENETICS; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; SURVIVAL ANALYSIS;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; MUTATION RATE; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84938709237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131046     Document Type: Article

References (44)

1. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9. doi: 10.1200/JCO.2010.33.5091 PMID: 21502544
2. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-62. doi: 10.1200/JCO.2011.38.0915 PMID: 22473155
3. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-34. doi: 10.1056/NEJMoa1305275 PMID: 24024839
4. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR,et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-7. doi: 10.1200/JCO.2013.53.2473 PMID: 24687833
5. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-14. doi: 10.1016/S0140-6736(11)60613-2 PMID: 21641636
6. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104: 856-62. doi: 10.1038/bjc.2011.19 PMID: 21285991
7. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014; 120: 1482-90. doi: 10.1002/cncr.28599 PMID: 24500602
8. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 2014; 25: 2008-14. doi: 10.1093/annonc/mdu252 PMID: 25009008
9. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies. Clin Cancer Res 2014; 20; 5322-30. doi: 10.1158/1078-0432.CCR-14-0332 PMID: 25139339
10. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, et al.BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. PLoS One 2013; 8: e84604. doi: 10.1371/journal.pone.0084604 PMID: 24367680
11. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105: 1151-6. doi: 10.1093/jnci/djt173 PMID: 23878352
12. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-9. PMID: 16024606
13. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3,EORTC 40993,SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74. doi: 10.1200/JCO.2009.23.3452 PMID: 20008640
14. Lemmens VE, de Haan N, Rutten HJ, Martijn H, Loosveld OJ, Roumen RM, Creemers GJ. Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008. Clin Exp Metastasis 2011; 28: 283-290. doi: 10.1007/s10585-010-9370-8 PMID: 21207120
15. van Steenbergen LN, Elferink MAG, Krijnen P, Lemmens VE, Siesling S, Rutten HJ, et al. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in the Netherlands 1989-2006. Ann Oncol 2010; 21: 2206-2212. doi: 10.1093/annonc/mdq227 PMID: 20439339
16. Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius B. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 2013; 24: 2354-60. doi: 10.1093/annonc/mdt197 PMID: 23704193
17. Mitry E, Rollot F, Jooste V, Guiu B, Lepage C, Ghiringhelli F, et al. Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer 2013; 49: 2919-25. doi: 10.1016/j.ejca.2013.04.001 PMID: 23642328
18. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen M, Wentzel-Larsen T Glimelius B. Clinical trial enrolment, patient characteristics, and survival differences in prospective registered metastatic colorectal cancer patients. Cancer 2009; 15: 4679-87.
19. Khattak MA, Townsend AR, Beeke C, Karapetis CS, Luke C, Padbury R, et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Eur J Cancer 2012; 48: 1293-98. doi: 10.1016/j.ejca.2011.09.029 PMID: 22119202
20. Kampf C, Olsson I, Ryberg U, Sjöstedt E, Pontén F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp 2012;pii: 3620. doi: 10.3791/3620 PMID: 22688270
21. Richman SD, Seymour MT, Chambers P, Elliot F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-7. doi: 10.1200/JCO.2009.22.4295 PMID: 19884549
22. Sundström M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 2010; 10: 660. doi: 10.1186/1471-2407-10-660 PMID: 21122130
23. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-17. PMID: 11886010
24. Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63. doi: 10.1016/j.ejca.2013.08.024 PMID: 24138831
25. Van Geel RV, Elez E, Bendell JC et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 2014; 32:5s (abstr 3514).
26. Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, et al. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One 2013; 8: e74950. doi: 10.1371/journal.pone.0074950 PMID: 24066160
27. Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas Network. Nature 2012; 487: 330-7. doi: 10.1038/nature11252 PMID: 22810696
28. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 2010; 127: 367-80 doi: 10.1002/ijc.25042 PMID: 19908233
29. Zhu Y, Yang SR, Wang PP, Savas S, Wish T, Zhao J, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer 2014; 110: 1359-66. doi: 10.1038/bjc.2014.6 PMID: 24448365
30. Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger J, Laird PW, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology 2013; 145: 348-56. doi: 10.1053/j.gastro.2013.05.001 PMID: 23665275
31. Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PLoS One 2011; 6: e21102. doi: 10.1371/journal.pone.0021102 PMID: 21738611
32. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, et al.Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128: 2075-84. doi: 10.1002/ijc.25555 PMID: 20635392
33. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120: 2316-24. doi: 10.1002/cncr.28729 PMID: 24737664
34. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: a tale of two sides or a continuum? Gut 2012; 61: 794-7. doi: 10.1136/gutjnl-2012-302014 PMID: 22490520
35. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32. doi: 10.1002/cncr.26086 PMID: 21456008
36. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer 2015 136: 83-90. doi: 10.1002/ijc.28955 PMID: 24806288
37. Rozek LS, Herron CM, Greenson JK, Moreno V, Capella G, Rennert G, Gruber SB. Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 838-43. doi: 10.1158/1055-9965.EPI-09-1112 PMID: 20200438
38. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010; 102: 1012-22. doi: 10.1093/jnci/djq201 PMID: 20587792
39. Schweiger T, Hegedüs B, Nikolowsky C, Hegedüs Z, Szirtes I, Mair R, et al. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Ann Surg Oncol 2014; 21: 946-54. doi: 10.1245/s10434-013-3386-7 PMID: 24281417
40. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013; 258: 619-26. doi: 10.1097/SLA.0b013e3182a5025a PMID: 24018645
41. Karagkounis G, Torbensen MS, Daniel HD, Azad NS, Diaz LA, Donehower RC, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013; 119: 4137-44. doi: 10.1002/cncr.28347 PMID: 24104864
42. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46: 1997-2009 doi: 10.1016/j.ejca.2010.03.036 PMID: 20413299
43. Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 2012 131: 980-6 doi: 10.1002/ijc.26467 PMID: 21960311
44. Price TJ, Hardingham JE, Lee CK, Weickhart A, Townsend AR, Wrin JW, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol. 2011; 29: 2675-82. doi: 10.1200/JCO.2010.34.5520 PMID: 21646616